APA (7th ed.) Citation

Furuhashi, M., Sakuma, I., Morimoto, T., Higashiura, Y., Sakai, A., Matsumoto, M., . . . Ueda, S. (2020). Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. Cardiovascular Diabetology, 19(1), 1. https://doi.org/10.1186/s12933-020-01061-0

Chicago Style (17th ed.) Citation

Furuhashi, Masato, et al. "Treatment with Anagliptin, a DPP-4 Inhibitor, Decreases FABP4 Concentration in Patients with Type 2 Diabetes Mellitus at a High Risk for Cardiovascular Disease Who Are Receiving Statin Therapy." Cardiovascular Diabetology 19, no. 1 (2020): 1. https://doi.org/10.1186/s12933-020-01061-0.

MLA (9th ed.) Citation

Furuhashi, Masato, et al. "Treatment with Anagliptin, a DPP-4 Inhibitor, Decreases FABP4 Concentration in Patients with Type 2 Diabetes Mellitus at a High Risk for Cardiovascular Disease Who Are Receiving Statin Therapy." Cardiovascular Diabetology, vol. 19, no. 1, 2020, p. 1, https://doi.org/10.1186/s12933-020-01061-0.